Partners to conduct first study using ctDNA-based minimal residual disease assessment for immunotherapy in the adjuvant non-small cell lung cancer setting.
Read More
FDA approval allows use of the Therascreen EGFR RGQ PCR kit as a companion diagnostic for Pfizer’s Vizimpro (dacomitinib) in patients with non-small cell lung cancer.
Read More
In a study of 1,048 patients, researchers found that the VeriStrat test is a significant predictor of patient outcomes, independent of mutation status, treatment received, and other clinical variables.
Read MoreQiagen has launched two novel liquid biopsy panels for the evaluation of circulating tumor cells, in the growing field of research into the molecular mechanisms of prostate and lung cancers.
Read More
Progress and challenges are on the way to a blood-based assay for PD-L1.
Read More